Portal de Periódicos da CAPES

Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131 I-LYM-1 Antibody

1998; Mary Ann Liebert, Inc.; Volume: 13; Issue: 4 Linguagem: Inglês

10.1089/cbr.1998.13.239

1557-8852

Gerald L. DeNardo, Sally J. DeNardo, Kathleen R. Lamborn, D. Goldstein, Nicolas Lévy, Jerry P. Lewis, L.F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P. McGahan, Stanley L. Mills, Sui Shen,

Radiopharmaceutical Chemistry and Applications

Cancer Biotherapy & RadiopharmaceuticalsVol. 13, No. 4 Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131I-LYM-1 AntibodyGerald L. DeNardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P. McGahan, Stanley L. Mills, and Sui ShenGerald L. DeNardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P. McGahan, Stanley L. Mills, and Sui ShenPublished Online:27 Mar 2009https://doi.org/10.1089/cbr.1998.13.239AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited ByBiological Therapies in the Treatment of Cancer—Update and New Directions28 October 2021 | International Journal of Molecular Sciences, Vol. 22, No. 21Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancersOncotarget, Vol. 11, No. 35A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models15 July 2020 | Clinical Cancer Research, Vol. 26, No. 14Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma20 December 2017 | International Journal of Molecular Sciences, Vol. 18, No. 12Radioimmunotherapy consolidation using 131 I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission28 August 2015 | Leukemia & Lymphoma, Vol. 57, No. 3Targeted Radionuclide TherapySingle-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model4 November 2015 | Frontiers in Medicine, Vol. 2Therapeutic radionuclides in nuclear medicine: current and future prospects16 October 2014 | Journal of Zhejiang University SCIENCE B, Vol. 15, No. 10Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma31 January 2013 | Cancer Chemotherapy and Pharmacology, Vol. 71, No. 4Radioimmunotherapy of Prostate Carcinoma19 July 2012Prostate Specific Membrane Antigen-Based Therapeutics10 December 2012Concepts, Consequences, and Implications of TheranosisSeminars in Nuclear Medicine, Vol. 42, No. 3Prostate-Specific Membrane Antigen-Based TherapeuticsAdvances in Urology, Vol. 2012Targeted Radionuclide Therapy—Expanded ContentAntibodies for Nuclear Medicine Therapy17 July 2012Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan2 August 2012Cancer radioimmunotherapyImmunotherapy, Vol. 3, No. 3PET/CT Imaging and Radioimmunotherapy of Prostate CancerSeminars in Nuclear Medicine, Vol. 41, No. 1Functions Used to Determine Absorbed Dose Given Activity Integrals7 February 2011Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a ParadigmSeminars in Nuclear Medicine, Vol. 40, No. 2Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer2 February 2010 | Cancer, Vol. 116, No. S4Tumor-Targeted Radioisotope TherapyImmunotherapy with Radio-immune ConjugatesA comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsBlood, Vol. 113, No. 20Targeted radionuclide therapy of cancerRadioimmunotherapy – still experimental? Rational, proven indications and future trendsmemo - Magazine of European Medical Oncology, Vol. 1, No. 4Update: Systemic Radiotherapy Can Cure Lymphoma: A Paradigm for Other Malignancies? Gerald L. Denardo, Sally J. Denardo, and Rod Balhorn4 September 2008 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 23, No. 4Antibody-based cancer therapy26 March 2008 | Expert Opinion on Drug Discovery, Vol. 3, No. 4Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?Future Oncology, Vol. 4, No. 2Effect of Antilymphoma Antibody, 131I-Lym-1, on Peripheral Blood Lymphocytes in Patients with Non-Hodgkin's Lymphoma Orazio Schillaci, Gerald L. DeNardo, Sally J. DeNardo, Desiree S. Goldstein, Linda A. Kroger, Robert T. O'Donnell, and Kathleen R. Lamborn9 November 2009 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 22, No. 4Technological Advances in RadioimmunotherapyClinical Oncology, Vol. 19, No. 6Lym-1-Induced Apoptosis of Non-Hodgkin's Lymphomas Produces Regression of Transplanted Tumors Nan Zhang, Leslie A. Khawli, Peisheng Hu, and Alan L. Epstein5 February 2009 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 22, No. 3Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasBlood, Vol. 109, No. 11Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current StatusJournal of Clinical and Experimental Hematopathology, Vol. 47, No. 2Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies22 February 2006 | Cancer Immunology, Immunotherapy, Vol. 55, No. 12Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2: therapeutic efficacy and myelotoxicityNuclear Medicine and Biology, Vol. 33, No. 8Cure of incurable lymphomaInternational Journal of Radiation Oncology*Biology*Physics, Vol. 66, No. 2Editorial: What Ails Solid Tumor Radioimmunotherapy? Chaitanya Divgi17 May 2006 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 21, No. 2Radioinmunoterapia en los linfomas no Hodgkin: desarrollo histórico y estado actualRevista Española de Medicina Nuclear, Vol. 25, No. 1Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma1 July 2009 | Leukemia & Lymphoma, Vol. 47, No. 12Splenic Volume Change and Nodal Tumor Response in Non-Hodgkin's Lymphoma Patients after Radioimmunotherapy Using Radiolabeled Lym-1 Antibody Sui Shen, Gerald L. DeNardo, Aina Yuan, Christine Hartmann-Siantar, Robert T. O'Donnell, and Sally J. DeNardo6 January 2006 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 20, No. 6α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212Pb-Labeled Radioimmunoconjugate Targeting HER2 Diane E. Milenic, Kayhan Garmestani, Erik D. Brady, Paul S. Albert, Dangshe Ma, Alia Abdulla, and Martin W. Brechbiel25 October 2005 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 20, No. 5Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies24 June 2016 | Technology in Cancer Research & Treatment, Vol. 4, No. 4Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab20 July 2005 | Clinical Cancer Research, Vol. 11, No. 14Treatment of Non-Hodgkin's Lymphoma (NHL) With Radiolabeled Antibodies (mAbs)Seminars in Nuclear Medicine, Vol. 35, No. 3Current status of cancer therapy with radiolabeled monoclonal antibodyAnnals of Nuclear Medicine, Vol. 19, No. 5Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspectiveSeminars in Oncology, Vol. 32Antilymphoma Effects of Anti-HLA-DR and CD20 Monoclonal Antibodies (Lym-1 and Rituximab) on Human Lymphoma Cells Cathy Liu, Gerald DeNardo, Evan Tobin, and Sally DeNardo15 November 2004 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, No. 5Radiometals as Payloads for Radioimmunotherapy for Lymphoma LymphomaClinical Lymphoma, Vol. 5Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodiesSeminars in Oncology, Vol. 31, No. 1Monoclonal Antibody Therapy in Lymphoid LeukemiasMonoclonal Antibody Therapy in Chronic Lymphocytic LeukemiaTumorimmunologieRadioimmunotherapy for non-Hodgkin's lymphomaSeminars in Oncology, Vol. 30, No. 4Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsBlood, Vol. 101, No. 9Advancing role of radiolabeled antibodies in the therapy of cancer11 March 2003 | Cancer Immunology, Immunotherapy, Vol. 52, No. 5Antibody therapy of non-Hodgkin's B-cell lymphoma28 February 2003 | Cancer Immunology, Immunotherapy, Vol. 52, No. 5Monoclonal Antibody Therapy for CancerAnnual Review of Medicine, Vol. 54, No. 1Radioimmunotherapy of non-Hodgkin lymphomasBlood, Vol. 101, No. 2Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma25 March 2003 | Cancer Investigation, Vol. 21, No. 2Radiolabeled antibodies for the management of metastatic cancerDevelopment of Radioimmunotherapy for the Treatment of Non-Hodgkin's Lymphoma1 December 2002 | International Journal of Hematology, Vol. 76, No. 5Radioimmunotherapy in non-Hodgkin lymphomaCurrent Opinion in Oncology, Vol. 14, No. 5Rationales, evidence, and design considerations for fractionated radioimmunotherapy12 February 2002 | Cancer, Vol. 94, No. S4Radiation Dosimetry for Radionuclide Therapy in a Nonmyeloablative Strategy Gerald L. DeNardo, Christine L. Hartmann Siantar, and Sally J. DeNardo5 July 2004 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 17, No. 1The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapyCritical Reviews in Oncology/Hematology, Vol. 39, No. 1-2Role of radiation dosimetry in radioimmunotherapy planning and treatment dosingCritical Reviews in Oncology/Hematology, Vol. 39, No. 1-2Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67Cu-2IT-BAT-Lym-1 Radioimmunotherapy Linda A. Kroger, Gerald L. DeNardo, Paul H. Gumerlock, Cheng Yi Xiong, Michelle D. Winthrop, Xu Bao Shi, Philip C. Mack, Tatiana Leshchinsky, and Sally J. DeNardo5 July 2004 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 16, No. 3Monoclonal Antibody Therapy for Lymphoma. An UpdateCancer Practice, Vol. 9, No. 2Antibody-Targeted Immunotherapy for Treatment of MalignancyAnnual Review of Medicine, Vol. 52, No. 1RadioimmunotherapyBioDrugs, Vol. 15, No. 3Radioimmunotherapy in the π-BCL1 B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone Timothy Illidge, Jamie Honeychurch, Anthony Vandersteen, and Mark Cragg29 January 2009 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 15, No. 6A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasBlood, Vol. 96, No. 9A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasBlood, Vol. 96, No. 9Are Radiometal-Labeled Antibodies Better Than Iodine-131–Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67–, Iodine-131–, and Yttrium-90–Labeled Lym-1 Antibody in Patients with Non-Hodgkin's LymphomaClinical Lymphoma, Vol. 1, No. 2Radioimmunotherapy in the Treatment of Non-Hodgkin's Lymphoma10 June 2013The Emerging Role Of Radioimmunotherapy In Haematological MalignanciesBritish Journal of Haematology, Vol. 108, No. 4A new era for radiolabeled antibodies in cancer?Current Opinion in Immunology, Vol. 11, No. 5Radioimmunotherapy of Acquired Immunodeficiency Syndrome (AIDS) Associated Lymphoma Robert T. O'Donnell, Bryan R. Leigh, Scott D. Christensen, Desireé S. Goldstein, David L. Kukis, Sui Shen, Aina Yuan, Diane A. DeNardo, Linda A. Kroger, and Gerald L. DeNardo29 January 2009 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 14, No. 3 Volume 13Issue 4Jan 1998 To cite this article:Gerald L. DeNardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P. McGahan, Stanley L. Mills, and Sui Shen.Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131I-LYM-1 Antibody.Cancer Biotherapy and Radiopharmaceuticals.Jan 1998.239-254.http://doi.org/10.1089/cbr.1998.13.239Published in Volume: 13 Issue 4: March 27, 2009PDF download